Angiotensin in treating brain conditions

Abstract

The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.

1 - 29 . (canceled) 
     
     
         30 . A method of treating stroke comprising
 administering to a subject suffering from stroke an angiotensin (1-7) peptide comprising the amino acid sequence Asp 1 -Arg 2 -Val 3 -Tyr 4 -Ile 5 -His 6 -Pro 7  (SEQ ID NO: 1) via systemic administration, wherein the systemic administration is not intracerebroventricular administration, and wherein the angiotensin (1-7) peptide is administered without the use of modified stem cells.   
     
     
         31 . The method of  claim 30 , wherein the systemic administration is oral administration. 
     
     
         32 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered via continuous infusion. 
     
     
         33 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered daily. 
     
     
         34 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered twice daily. 
     
     
         35 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered twice per month. 
     
     
         36 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered once per month. 
     
     
         37 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 1-1,500 ug/kg/day. 
     
     
         38 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 500-1,500 ug/kg/day. 
     
     
         39 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered at an effective dose ranging from about 800-1,200 ug/kg/day. 
     
     
         40 . The method of  claim 30 , wherein the angiotensin (1-7) peptide comprises one or more chemical modifications to increase protease resistance, serum stability and/or bioavailability. 
     
     
         41 . The method of  claim 40 , wherein the one or more chemical modifications comprise pegylation, acetylation, glycosylation, biotinylation, or substitution with D-amino acid or un-natural amino acid. 
     
     
         42 . The method of  claim 30 , wherein the systemic administration is selected from intravenous administration, subcutaneous administration, inhalation, intradermal administration, transdermal administration, and/or transmucosal administration. 
     
     
         43 . The method of  claim 42 , wherein the systemic administration is intravenous administration. 
     
     
         44 . The method of  claim 42 , wherein the systemic administration is subcutaneous administration. 
     
     
         45 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered as a component of a pharmaceutical composition comprising the angiotensin (1-7) peptide and a pharmaceutically acceptable excipient. 
     
     
         46 . The method of  claim 30 , wherein the angiotensin (1-7) peptide is administered as a part of a combination therapy including at least one additional therapeutic or treatment for traumatic brain injury. 
     
     
         47 . The method of  claim 46 , wherein the at least one additional therapeutic or treatment for traumatic brain injury is selected from a thrombolytic compound, an antioxidant, interferon beta-1a, interferon beta-1b, glatiramer acetate, mitoxantrone, natalizumab, fingolimod, and Teriflunomide, or combinations thereof.